PFE Q3 2026 Earnings Analysis
Pfizer raised FY26 guidance ($62-64B revenue, $2.95-3.05 EPS) on strong non-COVID (+7%) and acquired growth (+32%), supported by advancing pipeline targeting high single-digit CAGR through 2033.
Key Metrics
Wichtigste Erkenntnisse
- Strong non-COVID growth with 7% operational revenue growth and launched products up 32%
- Raised FY2026 revenue and EPS guidance, reflecting solid commercial execution and margin expansion
- Multiple late-stage pipeline programs advancing with Phase 3 readouts expected; path to high single-digit CAGR
Anhören auf
Verfügbar in
Transcript
// Full episode scriptWelcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex.
And I'm Jordan. Today we're diving into Pfizer's third quarter 2026 results, reported on November 3rd. And Alex, there's actually a leadership headline buried in here too.
There is, we'll get to that. But first, the standard stuff — this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.
Good, now let's get into it. Pfizer's got a lot going on this quarter.
It really does. Let's start with the numbers. Q3 revenue came in at $17.6 billion — I know the transcript says "$617 billion" but that's clearly a transcription error, context makes clear it's in the $17-18 billion range for the quarter. The real headline though: non-COVID revenue grew 7% operationally, and here's the kicker — their newer, launched and acquired products grew 32% operationally. That's a huge number.
And that 32% growth is really the story of this earnings call. We're talking about products like Padcev, which came from the Seagen acquisition, Nurtec for migraine from Biohaven, and Lorbrena in oncology. These aren't the legacy blockbusters — these are the bets Pfizer made to replace revenue they're going to lose to patent expirations.
Right, and speaking of those patent cliffs — Eliquis, Ibrance, Xtandi are all facing loss of exclusivity pressure in the next couple years. So this transition story is really about: can the new stuff grow fast enough to offset what's rolling off?
And based on this quarter, the answer looks like yes, at least for now. Adjusted EPS came in at $0.87, beating expectations, even with a $0.10 charge tied to the Innovent transaction. And because of that strength, management raised full-year revenue guidance to $62 billion to $64 billion, and bumped adjusted EPS guidance to $2.95 to $3.05.
Raising guidance is always a good sign — it tells you management has confidence in the back half of the year. Let's talk about the leadership change you mentioned.
Yeah, Cecile Guegan stepped in as the new CFO this quarter, bringing over 25 years of finance experience. She emphasized "financial discipline" and "rigorous capital allocation" — basically signaling continuity with the strategy Pfizer's been running, not a dramatic pivot.
That continuity matters because Pfizer's been in the middle of this massive productivity push — they're targeting $7.2 billion in net cost savings by the end of this year, and they've already announced a second phase targeting another $2.5 billion in savings from 2027 through 2029.
Which is important because, as one analyst pointed out on the call, total R&D and SG&A spending hasn't actually dropped much since 2022 — it's roughly flat around $24-25 billion. So the savings are happening, but they're getting plowed right back into R&D, especially oncology and obesity programs. Management's argument is these are "good" reinvestments, not wasted spend.
Let's talk pipeline, because this call had a lot of meaty clinical updates. The obesity program is clearly a big strategic bet — they're running 10 active or planned Phase 3 trials in 2026 for their GLP-1 franchise, including berobenatide, a monthly injectable they're hoping to get approved starting around 2028.
And in oncology, there were some really interesting data points. Elrexfio, their multiple myeloma drug, had a second positive Phase 3 readout. CEO Albert Bourla actually got pretty feisty about this during Q&A — he pointed out that Wall Street analysts are modeling around $600 million in peak sales for Elrexfio, while a competing drug with a similar profile is projected at $5 billion. He flat out said he thinks that gap isn't justified by the data.
That's a bold thing to say on an earnings call — basically telling analysts "you're underestimating us."
He did the same thing with Nurtec, their migraine drug — pointing out it's already annualizing near $2 billion, while Street estimates only have it reaching $2.5 billion by 2029. His broader point was that Pfizer's long-term guidance of a high single-digit revenue CAGR from 2028 through 2033 isn't just hopeful talk — he thinks the Street's models are simply behind on several products, both pipeline assets and already-launched drugs.
That's a useful thing for listeners to flag — when a CEO pushes back that specifically on analyst models, it's worth watching whether future quarters validate that confidence or not.
Right, it's a claim, not a guarantee. Let's also mention capital allocation quickly — Pfizer returned $7.3 billion to shareholders through dividends in the first nine months of the year, and leverage sits at 2.6 times, slightly below their target. New CFO Guegan reaffirmed that priorities remain: invest in the business, grow the dividend over time, and keep flexibility for buybacks down the road, though share repurchases look more like a post-2027 story once the patent cliff pressure eases.
And on the policy front, Bourla sounded notably calmer than a year ago — he said he's not expecting major changes to Most Favored Nation pricing rules given the split government outcome from today's election, which is a contrast to how nervous the industry was about tariffs and pricing policy back in 2025.
So what does this all mean for investors going forward? The transition story is intact — non-COVID growth is real, the new product portfolio is scaling fast, cost discipline is showing up in margins, and the pipeline has several binary catalysts coming in oncology, obesity, and immunology over the next 12 to 24 months.
But it's also a "show me" story — guidance for 2027 won't be formally issued until mid-December, and that's really the next big checkpoint, especially with Eliquis facing loss of exclusivity and IRA price negotiations kicking in.
Definitely something to watch. Before we wrap up — everything discussed is AI-generated analysis for educational purposes. Past performance doesn't guarantee future results. Please do your own due diligence.
Well said. Pfizer's got a lot of moving pieces right now — strong execution on the newer products, real cost discipline, and a pipeline that management is clearly betting big on. Whether the Street catches up to their confidence is the story we'll be watching into 2027 guidance season.
We'll be back to break down the next earnings call. Until then, this has been Beta Finch.
Thanks for listening, and we'll catch you next time.